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Abstract 
Background:  This systematic review aimed to evaluate the clinical outcomes and cost-effectiveness of left 
ventricular assist devices (LVADs) used as bridge to transplantation (BTT), compared to orthotopic heart 
transplantation (OHT) without a bridge. 
 
Method: Systematic searches were performed in electronic databases with available data extracted from text and 
digitized figures. Meta-analysis of short and long-term term post-transplantation outcomes was performed with 
summation of cost-effectiveness analyses.  
 
Results: Twenty studies reported clinical outcomes of 4,575 patients (1,083 LVAD BTT and 3,492 OHT). Five 
studies reported cost-effectiveness data on 837 patients (339 VAD BTT and 498 OHT). There was no difference 
in long-term post-transplantation survival (HR 1.24, 95% CI 1.00 – 1.54), acute rejection (HR 1.10, 95% CI 0.93 
– 1.30), or chronic rejection and cardiac allograft vasculopathy (HR 0.99, 95% CI 0.73 – 1.36). No differences 
were found in 30-day post-operative mortality (OR 0.91, 95% CI 0.42 – 2.00), stroke (OR 1.64, 95% CI 0.43 – 
6.27), renal failure (OR 1.43, 95% CI 0.58 – 3.54), bleeding (OR 1.56, 95% CI 0.78 – 3.13), or infection (OR 
2.44, 95% CI 0.81 – 7.38). Three of the five studies demonstrated incremental cost-effectiveness ratios below the 
acceptable maximum threshold. The total cost of VAD BTT ranged from $316,078 to $1,025,500, and OHT 
ranged from $179,051 to $802,200. 
 
Conclusion: LVADs used as BTT did not significantly alter post-transplantation long-term survival, rejection, and 
post-operative morbidity. LVAD BTT may be cost-effective, particularly in medium and high-risk patients with 
expected prolonged waiting times, renal dysfunction, and young patients. 
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Introduction 
End-stage heart failure (ESHF) is a major global health issue that continues to rise in prevalence, and is a 
significant contributor to health-care expenditure (1). Orthotopic heart transplantation (OHT) is the gold-standard 
treatment for ESHF and improves patient survival and quality of life (2). However, the availability of heart donors 
has failed to keep pace with rising demand for transplantation (3). The United Network for Organ Sharing 
(UNOS) data demonstrated that there remains a significant rate of death while patients await a donor organ (4). 
 
The use of a left ventricular assist device (LVAD) may improve survival and quality of life among ESHF patients 
refractory to optimal medical management (5). First generation LVADs, including the HeartMate I and Novacor 
N100, were primarily volume displacement devices, which pumped blood via a pulse generator, thus creating 
pulsatile flow. Second generation devices, including HeartMate II, Jarvik 2000, and Micromed DeBakey, were 
continuous axial flow pumps that resulted in non-pulsatile flow, with advantages of reduced size, improved 
durability and efficiency. Third and the latest generation of LVADs, including the HeartMate III, HeartWare 
HVAD, and DuraHeart, are distinguished by the use of a magnetically elevated impeller to create a contactless 
bearing. Increasingly, these devices are used in ESHF patients for bridge to transplantation (BTT) to improve 
survival until suitable donors are located. Due to the shortage of donor organs, there is mostly no alternative to 
LVAD as bridge to transplantation in most European countries and increasingly in the United States. The impact 
of LVADs on long-term post-transplantation outcomes remains unclear, and these devices carry a significant 
associated cost (6). The present systematic review and meta-analysis aimed to evaluate the short and long-term 
clinical outcomes and cost effectiveness of LVADs as BTT compared to OHT. 
 
Methods 
Search strategy 
Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (7), 
electronic searches were performed using Ovid Medline, Pubmed, Cochrane Central Register of Controlled Trials 
(CCTR), Cochrane Database of Systematic Reviews (CDSR), ACP Journal Club, and Database of Abstracts of 
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Review of Effectiveness (DARE), from their dates of inception to March 2016. To achieve maximum sensitivity 
of the search strategy, the terms “left ventricular assist device”, “bridge to transplantation”, “mechanical 
assistance”, “orthotopic heart transplant”, “inotrope”, “heart failure”, “cost-effectiveness”, “cost-utility”, 
“cost-benefit analysis”, “life-time cost”, “incremental cost-effectiveness ratio”, “quality adjusted life years”, 
and “life years” were combined as both text keywords and exploded MeSH headings where possible. Two 
authors (D.F.Z and M.S) performed the search independently, and any discrepancies were resolved by discussion. 
The reference lists of all retrieved articles were reviewed for further identification of potentially relevant studies, 
assessed using the inclusion and exclusion criteria. 
 
Selection criteria 
Eligible studies for the present systematic review were those that compared long-term post-transplantation 
survival outcomes or economic evaluations of cost-effectiveness between patients who received an LVAD as 
BTT, and those who underwent OHT without and LVAD as BTT (including patients that required intra-aortic 
balloon pump support or extracorporeal membrane oxygenation prior to transplantation). All LVAD generations 
were included in order to provide a comprehensive analysis and to maximise long-term outcomes available. For 
the meta-analysis of mortality and morbidity, only studies comparing LVADs against OHT and reporting actuarial 
survival rates were included. For the review of cost-effectiveness, only studies reporting incremental cost-
effectiveness ratios (ICERs) for LVADs compared to OHT were included. Studies that did not contain a 
comparative group or report relevant outcomes as endpoints were excluded. When institutions published duplicate 
studies with accumulating numbers of patients or increased lengths of follow-up, only the most complete reports 
were included for quantitative assessment. All publications were limited to those involving human subjects. 
Abstracts, case reports, conference presentations, editorials, reviews, and expert opinions were excluded. 
 
Data Extraction and Critical Appraisal 
All data were extracted from article texts, tables, and figures. Two investigators (D.F.Z and M.S) independently 
reviewed each included article. Because quality scoring is controversial in meta-analyses of observational studies, 
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two reviewers (D.F.Z and M.S) independently appraised each article included in our analysis according to a 
critical review checklist of the Dutch Cochrane Centre proposed by MOOSE (Supplementary Table 1) (8). 
Discrepancies between the two investigators were resolved by discussion and consensus with the senior authors 
(M.J.B and P.G.B). 
 
Outcomes 
The primary outcome was long-term post-transplantation survival in patients receiving LVAD BTT compared to 
OHT. Secondary outcomes included long-term acute rejection, chronic rejection or cardiac allograft vasculopathy, 
as well as 30-day post-operative mortality, stroke, renal failure, bleeding, and infection following transplantation. 
Acute rejection was defined as high-grade cellular allograft rejection of minimum grade 3A or 3B detected by 
endomyocardial biopsy according to the International Society for Heart & Lung Transplantation criteria (9-12). 
Chronic rejection or cardiac allograft vasculopathy was defined as greater than 50% occlusion of graft coronary 
arteries detected by post-transplantation coronary angiography (10-12). Post-operative stroke included all 
cerebrovascular accidents diagnosed by imaging (13). Renal failure was defined as new onset renal impairment 
following transplantation requiring haemodialysis (13). Bleeding was defined as post-transplantation 
haemorrhagic complications requiring reoperation (13). Infection was defined as the development of deep sternal 
infection or sepsis (14). All analysed outcomes included patients in United Network for Organ Sharing (UNOS) 
status 1 and 2. Additional outcomes for analysis of cost-effectiveness included ICERs, total cost, and quality-
adjusted life years (QALYs) or life years (LYs) gained for VADs compared to OHT. The cost-effectiveness 
threshold for VADs was set to $100,000 per QALY or LY, below which VADs are considered cost-effective and 
thus worth paying for (15-17). 
 
Statistical Analysis 
Long-term clinical outcomes were assessed using meta-analysis techniques described previously, with the hazard 
ratio (HR) used as a summary statistic to compare actuarial survival between groups (18, 19). Because not all 
studies report hazard ratios and confidence intervals, long-term survival and rejection rates were extracted by 
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digitizing the Kaplan-Meier curves presented in the included studies, using DigitizeIt Version 2.1.3 (Köln, 
Germany) and a spreadsheet developed by Tierney et al. (20). Aggregated Kaplan-Meier survival curves were 
created using the mean weighted digitized coordinates in Microsoft Excel (Microsoft, Redmond, WA). Pooled 
estimates and corresponding 95% confidence intervals (CI) were determined using inverse variance DerSimonian 
and Laird random-effects models.  
 
The reported incidence of post-operative outcomes were separately combined. Relative risk was chosen as a 
summary statistic with both fixed and random effects models tested, and the later presented due to its more 
conservative nature. The Mantel–Haenszel test was used to combine discrete data. Inverse variance-weighted 
averages were used for continuous data and logarithmic odds ratios (OR). All P values were two-sided. Additional 
tests include: χ2 to test heterogeneity between trials; I2 to estimate the percentage of total variation across studies 
due to heterogeneity rather than chance. Heterogeneity is substantial when I
2
 > 50%. Analysis for potential 
confounding factors was not performed due to the lack of raw data. Statistical analysis was conducted using 
Review Manager Version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen). 
 
The reported outcomes for cost-effectiveness were separately extracted using techniques previously described 
(21). All included cost-effectiveness studies employed Markov multi-state, decision-analytic, or novel decision-
analytic statistical modelling techniques for cost projections. These models accounted for medically 
treated/waiting states, VAD-BTT/OHT states, post-VAD and post-OHT complications, and death. Modelling of 
survival was based on previously published or national statistics, accounted for hemodynamic changes between 
states (HF waiting state to BTT-VAD vs BTT-VAD patients to OHT state), adjusted risk of death after post-
VAD/OHT complications, and captured life-time costs and risks. In addition, the statistical models also took into 
account device explantation, hypothetical worse case scenarios, and quality-of-life decrements. The total expense 
of VAD BTT and OHT calculated by each model included the costs of initial hospitalization, device, procedures, 
perioperative and long-term complications, repeat hospitalisations, physician fees, and drugs. All costs were 
reported in US Dollars and converted according to base-year currency exchange rates if necessary. Costs were 
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derived from government or hospital data (15, 22). Time horizons of all studies varied from 20 years (15) to 
lifetime (6, 22-24). Quality of life was measured using the EuroQOL 5 dimensions (EQ-5D) questionnaire (25). 
Mean ICER values less than $100,000 (± $130) were deemed cost-effective (15). Pearson’s product moment 
correlation coefficient (r) was used to assess the strength of association between total cost and QALYs gained for 
both VAD BTT and OHT. 
 
Results 
Literature Search 
A total of 1,874 studies were identified through six electronic database searches and from other sources including 
reference lists (Figure 1). After exclusion of duplicate or irrelevant references, 86 potentially relevant articles 
were retrieved. After application of inclusion and exclusion criteria, 25 relevant articles were included in the 
present review (6, 10-15, 22-24, 26-40). Twenty of these studies, including 4,575 patients (1,083 receiving LVAD 
BTT and 3,492 receiving OHT), were included in quantitative analysis of the post-operative and long-term 
outcomes. Characteristics of these studies are summarized in Table 1. Inspection of the funnel plot did not show 
significant asymmetry to suggest publication bias with the primary outcome selected (Supplementary Figure 1). 
Five studies, including 837 base-case patients (339 receiving VAD BTT and 498 receiving OHT), were included 
in quantitative analysis of cost-effectiveness data. Characteristics of these studies are summarised in Table 2. Full 
model descriptions, assumptions, and cost data in each included study are reported in Supplementary Table 2. 
 
Patient Characteristics 
In the 1980s-2000s study period, patients receiving LVAD BTT were significantly younger (LVAD BTT 
45.0±12.4, OHT 50.6±12.6, P <0.0001) and more likely to be male (89.7% vs 77.6%, P = 0.006). In the 1990s-
2000s study period, there was no significant difference between recipient age and gender. In the study period 
starting from year 2000, recipient age was similar in both comparison arms but there were significantly more male 
LVAD BTT recipients than those receiving OHT (80.5% vs 72.9%, P = 0.008). Overall, fewer LVAD BTT 
recipients had blood group A compared to OHT (33.9% vs 46.1%, P = 0.04), more had blood group type O 
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(50.5% vs 38.0%, P = 0.007), and more had percentage of panel-reactive antibody greater than 10 (30.5% vs 
10.7%, P <0.00001). All other baseline characteristics were similar in both comparison arms, including 
pulmonary capillary wedge pressure, mean pulmonary arterial pressure, cardiac index, pulmonary vascular 
resistance, ischemic cardiomyopathy, African-American or Caucasian ethnicity, blood group B or AB, positive 
test for cytomegalovirus, proportion of intra-aortic balloon pump support, donor organ ischemic time, and donor 
age (Table 3). One study reported extra-corporal membrane oxygenation support for LVAD BTT (30%) and OHT 
(5%) patients prior to transplantation(28). All patients in cost-effectiveness studies (not including reference or 
hypothetical patients for statistical modelling) had equal characteristics at baseline, including recipient age, 
proportion male, ischemic cardiomyopathy, implantable cardiac defibrillator or cardiac resynchronisation therapy, 
and Caucasian ethnicity (Supplementary Table 3).  
 
Long-Term Survival 
Five studies compared long-term post-transplantation survival for study period 1980s-2000s (11, 12, 30, 35, 36). 
There was significantly reduced post-transplantation survival following LVAD BTT compared to OHT (HR 1.48, 
95% CI 1.04 – 2.10, P = 0.03, I2 = 0%; Figure 2.1.1). 
 
Eleven studies compared long-term post-transplantation survival for study period 1990s-2000s (10, 13, 26-29, 32-
34, 37, 38). There was no significant difference between LVAD BTT and OHT (HR 1.13, 95% CI 0.81 – 1.57; 
Figure 2.1.2). There was substantial heterogeneity between the studies (I
2
 = 56%; heterogeneity P = 0.009).  
 
Four studies compared long-term post-transplantation survival for study period 2000s (14, 31, 39, 40). There was 
no significant difference between LVAD BTT and OHT (HR 1.13, 95% CI 0.81 – 1.58, I2 = 0%; Figure 2.1.3). 
 
Overall, 20 studies compared long-term post-transplantation survival, including all study periods (10-14, 26-40). 
The pooled HR demonstrated no significant difference (HR 1.24, 95% CI 1.00 – 1.54; Figure 2). There was 
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moderate heterogeneity between the studies (I
2
 = 37%; heterogeneity P = 0.05). An aggregate survival curve 
reconstructed from the digitised Kaplan-Meier curves in the included studies is presented in Figure 3. 
 
A subgroup analysis of five studies reporting the use of pre-transplant intra-aortic balloon pump found no 
significant difference in long-term survival between LVAD BTT and OHT (HR 0.88, 95% CI 0.42 – 1.84; I2 = 
67%; Supplementary Figure 2) (11, 13, 28, 31, 37). 
 
Rejection 
Eight studies compared long-term acute rejection (10-12, 27, 31-33, 37). There was no significant difference 
between LVAD BTT and OHT (HR 1.10, 95% CI 0.93 – 1.30, I2 = 10%; Figure 4.1.1).  
 
Four studies reported long-term chronic rejection and cardiac allograft vasculopathy (10, 12, 33, 37). There was 
no significant difference between LVAD BTT and OHT (HR 0.99, 95% CI 0.73 – 1.36, I2 = 32%; Figure 4.1.2). 
There was moderate heterogeneity between the studies (I
2
 = 32%; heterogeneity P = 0.22). 
 
Overall, eight studies compared long-term acute or chronic rejection between LVAD BTT and OHT (10-12, 27, 
31-33, 37). There was no significant difference between LVAD BTT and OHT (HR 1.08, 95% CI 0.95 – 1.23, I2 
= 10%; Figure 4).  
 
Post-operative Mortality and Morbidity 
Eleven studies reported 30 day post-operative mortality following transplantation (13, 14, 26-28, 31-33, 35, 36, 
40). There was no significant difference between LVAD BTT and OHT (OR 0.91, 95% CI 0.42 – 2.00; Figure 
5.1.1). There was moderate heterogeneity between the studies (I
2
 = 39%; heterogeneity P = 0.11). 
 
Two studies reported post-operative stroke rate (13, 14). There was no significant difference between LVAD BTT 
or OHT (OR 1.64, 95% CI 0.43 – 6.27; Figure 5.1.2). 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
Four studies reported post-operative renal failure (13, 14, 31, 40). There was no significant difference between 
LVAD BTT or OHT (OR 1.43, 95% CI 0.58 – 3.54, I2 = 0%; Figure 5.1.3). 
 
Four studies compared post-operative bleeding (13, 14, 26, 40). There was no significant difference between 
LVAD BTT or OHT (OR 1.56, 95% CI 0.78 – 3.13, I2 = 0%; Figure 5.1.4). 
 
Two studies reported post-operative infection rates (14, 40). There was no significant difference between LVAD 
BTT or OHT (OR 2.44, 95% CI 0.81 – 7.38; Figure 5.1.5). 
 
Cost-effectiveness 
Overall, five studies reported ICERs (costs required to gain one additional QALY or LY) for VAD BTT 
compared with OHT (6, 15, 22-24). In total, three of the five studies demonstrated ICERs consistent with cost-
effectiveness measured by QALY or LY (6, 15, 22) (Figure 6).  
 
Four studies reported ICERs specifically to gain one additional QALY (6, 22-24). These ranged from $89,790 to 
$414,275 per QALY gained. The results from two studies were below the threshold for cost-effectiveness 
($100,000) with ICERs of $89,790 (22) and $84,963 (6) (Figure 6).  
 
Four studies reported ICERs specifically to gain one additional LY (6, 15, 23, 24). These ranged from $72,475 to 
$351,528 per LY gained. The results from two studies were below ICER threshold for cost-effectiveness: high 
($85,899) and medium-risk ($100,128) VAD BTT patients analysed by Alba et al. (15), and patients reported by 
Clarke et al. ($72,475) (6) (Figure 6).  
 
Five studies reported the total cost of VAD BTT (range $316,078 to $1,025,500) and OHT (range $179,051 to 
$802,200) (6, 15, 22-24). Mean QALYs gained was reported by four studies for VAD BTT (range 3.27 to 7.32 
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years) and OHT (range 1.94 to 1.94 years) (6, 22-24). Mean LYs gained was reported by five studies for VAD 
BTT (range 5.46 to 16.87 years) and OHT (range 2.67 to 15.67 years) (6, 15, 22-24). There was a modest positive 
correlation between the total cost of VAD BTT and QALY gained (r = 0.69) (Figure 7A). The total cost of OHT 
was also positively correlated with QALY gained (r = 0.58) (Figure 7A). Scatter plot of total VAD BTT cost and 
QALY or LYs gained is shown in Figure 7B. The total cost of OHT is plotted against QALY or LYs gained in 
Figure 7C. Cost-effectiveness results are presented in Supplementary Table 4.   
 
Discussion 
The use of LVADs as BTT has been widely accepted as a viable therapy for ESHF patients awaiting heart 
transplantation. UNOS data has demonstrated there remains a significant rate of death while patients await a 
donor organ, and many patients are removed from the active list because they have medically deteriorated (4). To 
avoid adverse outcomes while awaiting heart transplantation, many centres have used LVADs as BTT in patients 
who are failing medical therapy with signs of deteriorating end-organ function. The number of transplant 
recipients supported mechanically increased from 19.1% in 2000 to 41% in 2012 (41). The impact of LVADs on 
post-transplantation outcomes, however, is variable. The perception among some transplantation centres is that 
LVAD implantation confers a more technically challenging reoperation for transplantation, and therefore might 
adversely affect postoperative outcomes. Conversely, LVAD therapy may improve end-organ perfusion and 
permit patients to recover from multi-organ failure, thus improving their preoperative status and outcome. The 
present meta-analysis found that there was no significant difference in post-operative mortality, stroke, renal 
failure, bleeding or infection, which supports the use of LVAD for BTT. 
 
This meta-analysis also demonstrated no significant difference in overall long-term survival, acute rejection, 
chronic rejection, and cardiac allograft vasculopathy post-transplant – again supporting the utility of LVADs in 
this context. There was significantly worse long-term survival in bridged patients in 1980s-2000s studies (HR 
1.48, 95% CI 1.04 – 2.10), however this difference was not present in later studies from 1990s-2000s and 2000s 
onwards. The reasoning for this difference is not clear, although it may be that earlier generations of LVADs did 
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not perform as well as later generations and clinical experience with these devices was lacking, which negatively 
impacted outcomes. In addition, there was a selection bias toward younger patients receiving bridging in the 
earlier studies (LVAD BTT 45.0±12.4 vs. OHT 50.6±12.6, P <0.0001), however this difference again disappeared 
in later studies. Younger age may indicate more severe pathology, different aetiology, or a difference in one of the 
pre-operative variables that was not measured. There were also a number of other differences in pre-operative 
patient characteristics, including lower proportion of blood group A, higher proportion of blood group O, and high 
proportion with RPA ≥ 10% (global allosensitisation), indicating the use of LVAD as BTT in a population where 
finding a suitable donor is more difficult and waiting time prolonged (42). Nonetheless overall survival was not 
significantly different, and survival in more recent studies using clinically relevant devices was not different, and 
thus results are encouraging. This is especially important considering the poor condition of many patients at the 
time of LVAD implantation and lack of treatment options. 
 
Unfortunately, it was not possible with the current data to meta-analyse the effect of duration of LVAD support 
on post-transplantation outcomes in detail. A sensitivity analysis that excluded studies with mean duration of 
support >200 days did not change the outcomes significantly (HR 1.23, 95% CI 0.93 – 1.63). However, a number 
of recent studies have found a negative impact on post-transplantation outcome with longer LVAD support times 
(43, 44). Fukahara et al. found that continuous-flow LVAD support for two years or more resulted in reduced 
survival at 30 days and two years post-transplantation, compared to patients who were supported for less than one 
year and one to two years (44). Multi-variable analysis also identified duration as a significant predictor of 
mortality at 2 years post-transplantation (HR 1.16; 95% CI 1.01-1.34) (44). Increased duration of pre-transplant 
support also exposes patients to increased rates of adverse events related to the device, which may contribute to 
reduced post-transplantation survival. This includes the adverse events related to continuous perfusion, including 
vascular remodeling, disruption of neuroendocrine feedback, impaired platelet function, and higher rates of 
bleeding (45, 46). However, the latest generation of devices have a number of design improvements aimed 
specifically at reducing these complications, including artificial pulsatility, reduced haemolysis and thrombosis, 
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and improved biocompatibility (47), which may facilitate longer support times without negative effects on post-
transplantation outcomes.  
 
A strategy of earlier LVAD implantation in patients on the donor waiting list may also prevent some of the 
attrition currently observed and improve functional status before transplantation. In fact, there has been a decrease 
in the number of patients transplanted in the first year of bridging, from 48% during a multicentre clinical trial to 
39% during the post-trial period (48). The results from a study using INTERMACS showed that following the 
approval of the Thoratec HeartMate II as BTT in the US, one-year pre-transplantation survival increased from 
73% in 2009 to 85% in 2011 (49). Other studies have shown that early LVAD implantation also reduces 
complications including bleeding and post-implantation right ventricular failure (50, 51), improves survival 
particularly in elderly patients (52), and improves functional status and quality of life (53). As such, further 
studies are required to determine the optimal device and timing of transplantation in BTT patients if they are to be 
performed in an increasingly elective setting. 
 
The development of minimally invasive LVAD operative techniques will also influence patient selection and 
post-transplantation outcomes. Some newer devices allow for intra-pericardial placement and no longer require 
creating a ‘pump pocket’, allowing for less invasive techniques and even off-pump insertion (54). One strategy is 
to combine a left anterolateral thoracotomy for pump insertion, with an upper hemi-sternotomy or second 
intercostal thoracotomy for outflow graft anastomosis. These approaches have particular benefits in BTT patients: 
they preserve the sternum for later transplantation, reduce the development of adhesions and makes explanation 
easier, and in patients with previous coronary artery bypass grafting reduces risk of damage to the grafts. The 
disadvantage of this technique however is the difficulty associated with smaller access to the left ventricular apex 
and ascending aorta, and difficulty with tunnelling the outflow graft. Nonetheless, these minimally invasive 
approaches continue to improve outcomes and enable procedures in higher risk patients. 
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With recent improvements in LVAD technology and ongoing debates about early implantation, there is increasing 
focus on its cost-effectiveness. An evaluation of the United States National Inpatient Sample from 2005 to 2009 
revealed marginal increase in OHT while the rate of LVAD implantation nearly tripled (55). During this period, 
the mean cost per patient increased 17% for LVAD and 40% for OHT. The cumulative LVAD cost also increased 
232% (from USD $143 million to $479 million) (55). With an ICER threshold of $100,000, three of the five 
studies in our review demonstrated that LVAD BTT may be cost-effective in patients who do successfully receive 
a transplant.  However, there were significant variations in reported ICER values. Although base year costs and 
currency exchange rates were controlled for, geographical, device, and hospitalization cost differences may have 
contributed to the observed variations in ICER. The Markov model economic analysis performed by Alba et al. 
(15) demonstrated that while VAD BTT improved survival at increased costs compared to non-bridged patients, 
bridging therapy may be cost-effective in certain populations: medium and high-risk patients with expected 
prolonged waiting times for transplantation, patients with existing renal dysfunction, those with a high risk of 
post-transplantation complications, and young patients. This finding was not replicated by a semi-Markov 
analysis of the British National Health Service (NHS) Blood and Transplant Database, in which continuous 
LVAD BTT delivered greater quality-adjusted life years at higher costs than medical management and was not 
found to be cost-effective (6). In a separate NHS database analysis, the newer HeartWare LVAD was found to be 
more cost-effective than HeartMate II for BTT (56). The impact of newer devices on survival outcomes and cost-
effectiveness remains an important question and deserves further investigation.   
 
Limitations 
The rapidly evolving technology of LVADs and the use of multiple device generations in later studies may have 
affected the results. Based on the available studies, the primary end-point was able to be separated into different 
time periods, which did demonstrate a difference. A proportion of LVAD BTT and OHT patients were supported 
by intra-aortic balloon pump (10.4% vs 13.2%) or ECMO (30% vs 5%) and the results should be interpreted with 
caution due to potentially worse OHT outcomes following mechanical support (57). In addition, all studies that 
met the inclusion criteria were observational, and consequently confounding bias may have affected the results. 
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Accuracy of the digital extraction and Kaplan-Meier curve reconstruction using the DigitizeIt software depends 
on the quality of the initial input image and the level of information provided by the publication. Unadjusted 
summary estimates were used for meta-analysis and confounders could not be ruled out. There was a moderate 
amount of heterogeneity in some outcomes, and these results should be interpreted with caution.  
 
Cost-effectiveness estimates were performed using different statistical modelling techniques and thus need to be 
interpreted with caution. These modelling techniques are not applicable in some countries with different LVAD 
funding models, and thus limits their relevance. Time horizon for cost estimates were long-term or life-time. 
Therefore, incremental cost estimates may vary depending on device technology, patient survival, and quality 
adjusted life years gained. The ICER threshold was selected based on current evidence from developed countries 
but may vary depending on a country’s health care system and allocation of available resources. 
 
Conclusions 
LVADs used as BTT in current practice do not significantly alter post-transplantation long-term survival, 
rejection, and post-operative morbidity, and are thus a viable therapy in this context. More data is required to 
determine the effect of duration of LVAD support on post-transplantation outcomes, and the optimal timing of 
LVAD implantation in patients with ESHF. In patients who do receive a transplant, some studies have 
demonstrated that LVADs used as BTT may be cost-effective, depending on the accepted ICER threshold. This is 
particularly relevant for medium and high-risk patients with expected prolonged waiting times for transplantation, 
patients with existing renal dysfunction, those with a high risk of post-transplantation complications, and young 
patients. 
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Figure Legends 
Figure 1. PRISMA flow chart of search strategy 
 
Figure 2. Forest plot of overall long-term post-transplantation survival associated with LVAD BTT compared to 
OHT. 
 
Figure 3. Overall Kaplan–Meier survival curves based on reconstructed individual study data. (A) Aggregated 
survival curves for LVAD BTT compared with OHT. (B) Long-term post-transplantation survival of the LVAD 
BTT cohort, reconstructed from 1083 patients. (C) Long-term post-transplantation survival of the OHT cohort, 
reconstructed from 3492 patients. 
 
Figure 4. Forest plot of overall long-term post-transplantation acute and chronic rejection with LVAD BTT 
compared to OHT. 
 
Figure 5. Forest plot of post-operative mortality and morbidity following transplantation with LVAD BTT 
compared to OHT. 
 
Figure 6. Mean ICER (BTT-OHT) for QALY and LY compared to threshold for cost-effectiveness. 
 
Figure 7. Scatter plot of (A) total cost of VAD BTT or OHT per QALY gained, (B) total cost of VAD BTT per 
QALY or LY gained, and (C) total cost of OHT per QALY or LY gained. 
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Table 1. Study characteristics for assessment of post-operative and long-term outcomes in patients receiving LVAD bridge-to-transplantation vs. 
orthotopic heart transplantation. 
First 
Author 
Year Study Period Country N 
LVAD 
BTT 
N OHT Device Type Mean 
Support 
Duration 
(Days) 
Maximum 
Follow-up 
(Years) 
Study 
Design 
Massad [26] 1996 1992-1996 USA 53 203 Heartmate 72 (median) 3  OS, R 
Mehta [27] 1996 1992-1995 USA 19 73 Pierce-Donachy, Heartmate NR 2 OS, R 
Aaronson 
[28] 
2002 1996-2001 USA 66 38 Heartmate pneumatic  NR 5 OS, R 
John [10] 2003 1992-1999 USA 105 416 NR 94±51 8  OS, R 
Schmid [29] 2003 1994-2000 Germany 41 146 Novacor, Heartmate, 
DeBakey, Thoratec 
215±86 7  OS, R 
Vitali [30] 2003 1985-2001 Italy 53 501 Novacor, DeBakey 84 ± 168 17  OS, R 
Carrier [31] 2004 2000-2002 Canada 13 20 Thoratec 17±19 1 OS, R 
Baran [11] 2005 1989-2002 USA 26 220 Novacor 78±71 10 OS, R 
Fernandez 
[32] 
2005 1997-2001 USA 15 67 Novacor 174 (4-497) 4.1 OS, R 
Pamboukian 2005 1994-2001 USA 48 50 Heartmate 87 (3-493) 6.8 OS, R 
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[33] 
Gonzalez- 
Stawinski 
[34] 
2006 1996-2002 USA 125 113 Heartmate, Novacor, 
Thoratec, DeBakey, Jarvik 
110 (1-1030) 8 OS, R 
Cleveland 
[35] 
2008 1986-2006 USA 23 294 Heartmate VE, XVE 165±122 19 OS, R 
Kirsch [12] 2008 1985-2007 Belgium 30 318 Novacor 172.3±111.1 10 OS, R 
Liden [36] 2009 1988-2007 Sweden 11 22 Heartmate VE, DeBakey, 
Jarvik, VentrAssist 
239 (24-1002) 4 OS, R 
Pal [13] 2009 1994-2007 USA 86 173 Pulsatile-flow device, 
continuous-flow device 
59±32 8.3 OS, R 
Sasaki [37] 2009 1990-2005 USA 31 149 Heartmate pneumatic, 
vented-electric 
103±91 5 OS, R 
Bull [38] 2010 1993-2009 USA 45 156 Heartmate I, II NR 15 OS, R 
Williams 
[14] 
2011 2009-2009 USA 29 13 Continuous-flow LVAD 116±143 1 OS, R 
Uriel [39] 2013 2001-2011 USA 227 451 HeartMate I and II, 
DuraHeart, DeBakey, 
Toyobo, VentrAssist 
208±199 10 OS, R 
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Deo [40] 2014 2007-2011 USA 37 69 Heartmate II, Jarvik, 
VentrAssist, DuraHeart 
227 (153-328) 5 OS, R 
 
LVAD, left ventricular assist device; BTT, bridge to transplantation; OHT, orthotopic heart transplantation; OS, observational study; R, 
retrospective; RS, randomized study; P, prospective; NR, not reported 
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Table 2. Study characteristics for assessment of cost-effectiveness in patients receiving VAD bridge-to-transplantation vs. orthotopic heart 
transplantation. 
First 
Author 
Year Country Institution/ 
Database 
Device Analysis Time-
Horizon 
N Currency conversion 
BTT OHT 
Sharples 
[22] 
2006 UK EVAD-UK Heartmate VE, 
Thoratec,  
Multi-state Markov 
model
a, b
 
Life-time 70 71 1 £ = US$1.8182 
Moreno 
[23] 
2012 UK EVAD-UK HeartMate II Multistate 
probabilistic 
Markov model
a, c, d
 
Life-time 70 71 1 £ = US$1.6 
Alba 
[15] 
2013 Canada Toronto 
General 
Hospital 
HeartMate II, 
HeartWare, 
DuraHeart 
Decision analytic 
Markov model
e
 
20 years 34 120 Estimated US$1 = 
CDN$0.989
f
 
Clarke 
[6] 
2014 UK NHS BTT 
Program 
HeartWare 
HLVAD, Thoratec 
HeartMate II, 
Jarvik 2000 
FlowMaker, 
Micromed 
HeartAssist 
Semi-Markov 
multi-state model
a
 
Life-time 235 307 Estimated 1 £ = US$1.6
g
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Long
g 
[24] 
2014 USA NR NR Novel decision-
analytic, state-
transition model
a, h
 
Life-time 20000 
simulated 
patients 
NR 
 
a
Constant hazard rate assumed for analysis in statistical model; 
b
comparative data taken from concurrent, hospitalized inotrope-dependent or 
urgent listed transplant candidates and a hypothetical worst-case scenario (all VAD-eligible patients die within 30 days in the absence of VADs);  
c
estimates of survival for LVAD group obtained from Pagani et al.; 
d
comparative survival data taken from US Scientific Registry of Transplant 
Recipients 2000-2005, 
e
comparison data included UNOS database, International Society of Heart and Lung Transplantation registry (ISHLT), 
INTERMACS, the United Kingdom database, and a systematic literature review; 
f
average 2011 US Dollar (noon) exchange rate from Bank of 
Canada; 
g
currency exchange value provided by Moreno et al.; 
g
only heart transplant eligible patients were included for this systematic review; 
h
contemporary survival rates for LVAD patients were obtained from INTERMACS, OHT survival from ISHLT 
 
LVAD, left ventricular assist device; BTT, bridge to transplantation; OHT, orthotopic heart transplantation; NR, not reported 
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Table 3. Baseline characteristics for assessment of post-operative and long-term outcomes in patients receiving LVAD bridge-to-transplantation 
vs. orthotopic heart transplantation.  
Baseline parameter LVAD BTT OHT 
RR or WMD  
(95% CI) 
Overall  
P-value 
Recipient age (years) 50.0±13.2 50.7±12.7 -1.84 (-3.16, -0.52) 0.006 
Study Period 1980s-2000s 45.0±12.4 50.6±12.6 -5.21 (-7.75, -2.68) <0.0001 
Study Period 1990s-2000s 49.4±14.0 50.2±13.2 -1.12 (-2.58, 0.34) 0.13 
Study Period 2000s 52.2±12.0 52.0±11.9 -0.73 (3.65, 2.18) 0.62 
% Male 82.1 76.1 1.11 (1.04, 1.18) 0.002 
Study Period 1980s-2000s 89.7 77.6 1.17 (1.00, 1.37) 0.006 
Study Period 1990s-2000s 81.8 76.2 1.08 (0.99, 1.18) 0.07 
Study Period 2000s 80.5 72.9 1.10 (1.03, 1.18) 0.008 
PCWP (mmHg) 20.8±7.6 24.0±7.5 -0.07 (-3.98, 3.84) 0.97 
MPAP (mmHg) 34.1±9.1 37.2±8.9 -0.43 (-2.41, 1.54) 0.67 
CI (L/min/m
2
) 2.1±0.6 2.0±0.6 -0.15 (-0.44, 0.14) 0.30 
PVR (Wood U) 2.8±1.5 3.4±1.4 -0.12 (-0.36, 0.12) 0.34 
% ICM 60.8 41.8 1.14 (0.93, 1.41) 0.21 
% African-American 25.0 19.1 1.08 (0.62, 1.86) 0.79 
% Caucasian  82.2 82.6 1.00 (0.89, 1.13) 0.99 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
% Blood group A 33.9 46.1 0.75 (0.57, 0.99) 0.04 
% Blood group B 11.9 10.1 1.19 (0.67, 2.13) 0.55 
% Blood group AB 3.7 5.7 0.75 (0.29, 1.97) 0.56 
% Blood group O 50.5 38.0 1.35 (1.09, 1.68) 0.007 
% CMV positive 68.5 67.8 1.02 (0.84, 1.24) 0.83 
% PRA ≥ 10 30.5 10.7 3.84 (2.71, 5.42) <0.00001 
% IABP 10.4 13.2 0.65 (0.08, 4.99) 0.68 
Ischemic time 183.8±55.5 165.0±52.4 19.10 (-0.51, 38.72) 0.06 
Donor age 32.0±12.0 33.4±12.6 -1.10 (-4.76, 2.56) 0.56 
 
LVAD, left ventricular assist device; BTT, bridge to transplantation; OHT, orthotopic heart transplantation; PCWP, pulmonary capillary wedge 
pressure, MPAP, mean pulmonary arterial pressure; CI, cardiac index; PVR, pulmonary vascular resistance; ICM, ischemic cardiomyopathy; 
CMV, cytomegalovirus; PRA, panel-reactive antibody; IABP, intra-aortic balloon pump; RR, risk ratio; WMD, weighted mean difference; CI, 
confidence interval 
